FDA Greenlights RAPT's Next-Gen Food Allergy Treatment Trial

FDA OKs major trial (prestIgE) for RPT904, a next-gen anti-IgE drug. It will treat ~100 people allergic to peanut, milk, or egg. The goal is a better, safe therapeutic option by blocking IgE, the key driver of these allergies.

FDA Greenlights RAPT's Next-Gen Food Allergy Treatment Trial
"Strawberries" Photo by Jonathan Cooper on Unsplash
Already have an account? Sign in.